Evidence map›Paper›PMID 31351666›Full record

ArticleEuropean urology2019

Tumour Heterogeneity and Resistance to Therapy in Prostate Cancer: A Fundamental Limitation of Prostate-specific Membrane Antigen Theranostics or a Key Strength?

Michael S Hofman, Louise Emmett

Registry-linked trialAbstract readEditorialComment
PubMed Publisher
In one paragraph

Article in European urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04873427 (In Situ Clonal Heterogeneity in Prostatic Diagnostic Biopsies), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04873427 terminatednot on this mapstarted 2021, after this paper: background citation

In Situ Clonal Heterogeneity in Prostatic Diagnostic Biopsies: Impact on Prostate Cancer Evolution and Clinical Outcome. A Retrospective, Proof of Concept Study

TypeobservationalSponsorClinica Luganese MoncuccoRan2021 to 2023Enrolled40ConditionsProstate Cancer, Genetic PredispositionArmsclonal heterogeneity evaluation
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. A prospective intra-individual comparison of [European journal of nuclear medicine and molecular imaging · 2021
    Article
  5. Diagnostic Value ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Michael S HofmanMolecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia. Electronic address: michael.hofman@petermac.org.
Louise EmmettTheranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Prostatic NeoplasmsTheranostic NanomedicineDNA RepairHumansMale

Identifiers

PMID31351666

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.